's stock had its "outperform" rating restated by equities research analysts at Oppenheimer in a research note issued to investors on Monday. They currently have a $48.00 price objective on the stock.
http://ift.tt/197skJZ
http://ift.tt/197skJZ
Stem Cell Research News: News on Stem Cell Research continually updated from thousands of sources around from the B Media Network.
No comments:
Post a Comment